Hutchmed, Innovent Biologics announce China NMPA approval for NDA

Innovent Biologics and Hutchmed (HCM) jointly announce that the new drug application for the combination of Tyvyt and Elunate has been granted approval by the China National Medical Products Administration for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor-tyrosine kinase inhibitors therapy and have not received programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy in the first-line setting.